Braveheart Bio seeks $319M in US IPO backed by a16z

Braveheart Bio's rapid IPO pursuit highlights the growing trend of biotech firms leveraging strategic partnerships and global data to expedite drug development.
The post Braveheart Bio seeks $319M in US IPO backed by a16z appeared first on Crypto Briefing.
This content is automatically aggregated. Full credit goes to the original publisher (cryptobriefing.com).

